Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Otorhinolaryngology

  Free Subscription


Articles published in Radiother Oncol

Retrieve available abstracts of 95 articles:
HTML format
Text format



Single Articles


    May 2018
  1. WINTER RM, Leibfarth S, Schmidt H, Zwirner K, et al
    Assessment of image quality of a radiotherapy-specific hardware solution for PET/MRI in head and neck cancer patients.
    Radiother Oncol. 2018 May 7. pii: S0167-8140(18)30209.
    PubMed     Text format     Abstract available


  2. MICHIELS S, Poels K, Crijns W, Delombaerde L, et al
    Volumetric modulated arc therapy of head-and-neck cancer on a fast-rotating O-ring linac: Plan quality and delivery time comparison with a C-arm linac.
    Radiother Oncol. 2018 May 5. pii: S0167-8140(18)30212.
    PubMed     Text format     Abstract available


  3. VAN DEN BOSCH S, Vogel WV, Raaijmakers CP, Dijkema T, et al
    Implications of improved diagnostic imaging of small nodal metastases in head and neck cancer: Radiotherapy target volume transformation and dose de-escalation.
    Radiother Oncol. 2018 May 3. pii: S0167-8140(18)30211.
    PubMed     Text format     Abstract available


    April 2018
  4. MURTHY V, Lewis S, Kannan S, Khadanga CR, et al
    Submandibular function recovery after IMRT in head and neck cancer: A prospective dose modelling study.
    Radiother Oncol. 2018 Apr 30. pii: S0167-8140(18)30113.
    PubMed     Text format     Abstract available


  5. GREGOIRE V, Grau C
    In reply to "A Long-Awaited Guideline for the Delineation of Primary Tumor in Head and Neck Cancer, and a Few Concerns about It" by Sezin Yuce Sari et al.
    Radiother Oncol. 2018 Apr 27. pii: S0167-8140(18)30175.
    PubMed     Text format    


  6. YUCE SARI S, Yeginer M, Cengiz M
    A long-awaited guideline for the delineation of primary tumor in head and neck cancer, and a few concerns about it.
    Radiother Oncol. 2018 Apr 24. pii: S0167-8140(18)30177.
    PubMed     Text format    


    March 2018
  7. TAN TH, Soon YY, Cheo T, Ho F, et al
    Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
    Radiother Oncol. 2018 Mar 16. pii: S0167-8140(18)30123.
    PubMed     Text format     Abstract available


  8. SHURYAK I, Hall EJ, Brenner DJ
    Dose dependence of accelerated repopulation in head and neck cancer: Supporting evidence and clinical implications.
    Radiother Oncol. 2018 Mar 10. pii: S0167-8140(18)30098.
    PubMed     Text format     Abstract available


  9. FANG P, Jiang W, Davuluri R, Xu C, et al
    High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer.
    Radiother Oncol. 2018 Mar 9. pii: S0167-8140(18)30117.
    PubMed     Text format     Abstract available


  10. OVERGAARD J, Hoff CM, Hansen HS, Specht L, et al
    DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
    Radiother Oncol. 2018 Mar 6. pii: S0167-8140(18)30105.
    PubMed     Text format     Abstract available


  11. HE J, Cai L, Chen Y, He Y, et al
    Antitumor and radiosensitizing effects of SKLB-163, a novel benzothiazole-2-thiol derivative, on nasopharyngeal carcinoma by affecting the RhoGDI/JNK-1 signaling pathway.
    Radiother Oncol. 2018 Mar 5. pii: S0167-8140(18)30063.
    PubMed     Text format     Abstract available


    January 2018
  12. IQBAL MS, Kelly C, Kovarik J, Goranov B, et al
    Palliative radiotherapy for locally advanced non-metastatic head and neck cancer: A survey of UK national practice.
    Radiother Oncol. 2018 Jan 20. pii: S0167-8140(17)32734.
    PubMed     Text format    


  13. SHAHID IQBAL M, Kelly C, Kovarik J, Goranov B, et al
    Palliative radiotherapy for locally advanced non-metastatic head and neck cancer: A systematic review.
    Radiother Oncol. 2018 Jan 19. pii: S0167-8140(17)32766.
    PubMed     Text format     Abstract available


  14. PAULINO AC, Mahajan A, Ye R, Grosshans DR, et al
    Ototoxicity and cochlear sparing in children with medulloblastoma: Proton vs. photon radiotherapy.
    Radiother Oncol. 2018 Jan 17. pii: S0167-8140(18)30017.
    PubMed     Text format     Abstract available


  15. ADENIS A, Castan F, Conroy T
    Consolidation chemotherapy after definite concurrent chemoradiation in patients with non-operable esophageal cancer: Is it useful?
    Radiother Oncol. 2018 Jan 10. pii: S0167-8140(17)32773.
    PubMed     Text format    


  16. CHEN Y, Wang J
    Concurrent chemoradiotherapy alone is feasible for esophageal squamous cell carcinoma patients not suitable for surgery.
    Radiother Oncol. 2018 Jan 10. pii: S0167-8140(17)32774.
    PubMed     Text format    


  17. NEVENS D, Duprez F, Bonte K, Deron P, et al
    Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Reply to Elicin et al.
    Radiother Oncol. 2018 Jan 4. pii: S0167-8140(17)32770.
    PubMed     Text format    


    December 2017
  18. ZHANG Y, Li WF, Liu X, Chen L, et al
    Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial.
    Radiother Oncol. 2017 Dec 16. pii: S0167-8140(17)32756.
    PubMed     Text format     Abstract available


  19. SHIRAISHI Y, Fang P, Xu C, Song J, et al
    Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy.
    Radiother Oncol. 2017 Dec 13. pii: S0167-8140(17)32751.
    PubMed     Text format     Abstract available


  20. KAMAL M, Rosenthal DI, Volpe S, Goepfert RP, et al
    Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors.
    Radiother Oncol. 2017 Dec 8. pii: S0167-8140(17)32691.
    PubMed     Text format     Abstract available


    November 2017
  21. LEE AW, Ng WT, Pan JJ, Poh SS, et al
    International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma.
    Radiother Oncol. 2017 Nov 15. pii: S0167-8140(17)32686.
    PubMed     Text format     Abstract available


  22. BOGOWICZ M, Leijenaar RTH, Tanadini-Lang S, Riesterer O, et al
    Post-radiochemotherapy PET radiomics in head and neck cancer - The influence of radiomics implementation on the reproducibility of local control tumor models.
    Radiother Oncol. 2017 Nov 6. pii: S0167-8140(17)32663.
    PubMed     Text format     Abstract available


  23. TAKAHASHI N, Umezawa R, Takanami K, Yamamoto T, et al
    Whole-body total lesion glycolysis is an independent predictor in patients with esophageal cancer treated with definitive chemoradiotherapy.
    Radiother Oncol. 2017 Nov 3. pii: S0167-8140(17)32659.
    PubMed     Text format     Abstract available


    October 2017
  24. CEREDA E, Cappello S, Colombo S, Klersy C, et al
    Nutritional counseling with or without systematic use of oral nutritional supplements in head and neck cancer patients undergoing radiotherapy.
    Radiother Oncol. 2017 Oct 27. pii: S0167-8140(17)32655.
    PubMed     Text format     Abstract available


  25. OU D, Garberis I, Adam J, Blanchard P, et al
    Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy.
    Radiother Oncol. 2017 Oct 24. pii: S0167-8140(17)32647.
    PubMed     Text format     Abstract available


  26. DE-COLLE C, Menegakis A, Monnich D, Welz S, et al
    SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy.
    Radiother Oncol. 2017 Oct 20. pii: S0167-8140(17)32648.
    PubMed     Text format     Abstract available


  27. RAO AD, Coquia S, De Jong R, Gourin C, et al
    Effects of biodegradable hydrogel spacer injection on contralateral submandibular gland sparing in radiotherapy for head and neck cancers.
    Radiother Oncol. 2017 Oct 3. pii: S0167-8140(17)32584.
    PubMed     Text format     Abstract available


    September 2017
  28. MICHIELS S, Barragan AM, Souris K, Poels K, et al
    Patient-specific bolus for range shifter air gap reduction in intensity-modulated proton therapy of head-and-neck cancer studied with Monte Carlo based plan optimization.
    Radiother Oncol. 2017 Sep 23. pii: S0167-8140(17)32568.
    PubMed     Text format     Abstract available


  29. WOPKEN K, Bijl HP, Langendijk JA
    Prognostic factors for tube feeding dependence after curative (chemo-) radiation in head and neck cancer: A systematic review of literature.
    Radiother Oncol. 2017 Sep 21. pii: S0167-8140(17)32545.
    PubMed     Text format     Abstract available


  30. CHANG CL, Tsai HC, Lin WC, Chang JH, et al
    Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma.
    Radiother Oncol. 2017 Sep 15. pii: S0167-8140(17)32548.
    PubMed     Text format     Abstract available


  31. SHIRAISHI Y, Xu C, Yang J, Komaki R, et al
    Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy.
    Radiother Oncol. 2017 Sep 13. pii: S0167-8140(17)32550.
    PubMed     Text format     Abstract available


    August 2017
  32. YANG H, Chen X, Lin S, Rong J, et al
    Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
    Radiother Oncol. 2017 Aug 29. pii: S0167-8140(17)32479.
    PubMed     Text format     Abstract available


  33. LOCK S, Perrin R, Seidlitz A, Bandurska-Luque A, et al
    Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
    Radiother Oncol. 2017 Aug 23. pii: S0167-8140(17)32517.
    PubMed     Text format     Abstract available


  34. FERRIS MJ, Zhong J, Switchenko JM, Higgins KA, et al
    Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy.
    Radiother Oncol. 2017 Aug 18. pii: S0167-8140(17)32515.
    PubMed     Text format     Abstract available


  35. TONLAAR N, Galoforo S, Thibodeau BJ, Ahmed S, et al
    Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer.
    Radiother Oncol. 2017 Aug 16. pii: S0167-8140(17)32501.
    PubMed     Text format     Abstract available


  36. HAWKINS PG, Lee JY, Mao Y, Li P, et al
    Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life.
    Radiother Oncol. 2017 Aug 16. pii: S0167-8140(17)32502.
    PubMed     Text format     Abstract available


  37. HUIZING FJ, Hoeben BAW, Franssen G, Lok J, et al
    Preclinical validation of 111In-girentuximab-F(ab')2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts.
    Radiother Oncol. 2017 Aug 5. pii: S0167-8140(17)32484.
    PubMed     Text format     Abstract available



  38. Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison.
    Radiother Oncol. 2017;124:232-239.
    PubMed     Text format     Abstract available


  39. MAVROIDIS P, Price A, Fried D, Kostich M, et al
    Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer.
    Radiother Oncol. 2017;124:240-247.
    PubMed     Text format     Abstract available


  40. GUTTMANN DM, Frick MA, Carmona R, Deville C Jr, et al
    A prospective study of proton reirradiation for recurrent and secondary soft tissue sarcoma.
    Radiother Oncol. 2017;124:271-276.
    PubMed     Text format     Abstract available


    July 2017
  41. MOHAMED ASR, Cardenas CE, Garden AS, Awan MJ, et al
    Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.
    Radiother Oncol. 2017 Jul 31. pii: S0167-8140(17)32476.
    PubMed     Text format     Abstract available


  42. ZHAI TT, van Dijk LV, Huang BT, Lin ZX, et al
    Improving the prediction of overall survival for head and neck cancer patients using image biomarkers in combination with clinical parameters.
    Radiother Oncol. 2017 Jul 29. pii: S0167-8140(17)32472.
    PubMed     Text format     Abstract available


  43. NEVENS D, Duprez F, Bonte K, Deron P, et al
    Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Tumor control and late toxicity.
    Radiother Oncol. 2017 Jul 26. pii: S0167-8140(17)32470.
    PubMed     Text format     Abstract available


  44. NEVENS D, Duprez F, Daisne JF, De Neve W, et al
    Dose de-escalation to the elective lymph nodes in head and neck cancer. Reply to Amdur et al.
    Radiother Oncol. 2017 Jul 24. pii: S0167-8140(17)32456.
    PubMed     Text format    


  45. RASSAMEGEVANON T, Lock S, Range U, Krause M, et al
    Tumor heterogeneity determined with a gammaH2AX foci assay: A study in human head and neck squamous cell carcinoma (hHNSCC) models.
    Radiother Oncol. 2017 Jul 21. pii: S0167-8140(17)32447.
    PubMed     Text format     Abstract available


  46. XI M, Xu C, Liao Z, Hofstetter WL, et al
    The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy.
    Radiother Oncol. 2017 Jul 4. pii: S0167-8140(17)30428.
    PubMed     Text format     Abstract available


    June 2017
  47. ZHANG D, Zhang W, Liu W, Mao Y, et al
    Human papillomavirus infection increases the chemoradiation response of esophageal squamous cell carcinoma based on P53 mutation.
    Radiother Oncol. 2017 Jun 21. pii: S0167-8140(17)30408.
    PubMed     Text format     Abstract available


  48. MCLAY M, Stedford A, Yurkowski E, Matlock S, et al
    Population-based assessment of relationship between volume of practice and outcomes in head and neck cancer patients treated in a provincially coordinated radiotherapy program.
    Radiother Oncol. 2017 Jun 15. pii: S0167-8140(17)30401.
    PubMed     Text format     Abstract available


  49. ZHANG W, Zhang X, Yang P, Blanchard P, et al
    Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer.
    Radiother Oncol. 2017;123:401-405.
    PubMed     Text format     Abstract available


  50. CHEN AM, Chin R, Beron P, Yoshizaki T, et al
    Inadequate target volume delineation and local-regional recurrence after intensity-modulated radiotherapy for human papillomavirus-positive oropharynx cancer.
    Radiother Oncol. 2017;123:412-418.
    PubMed     Text format     Abstract available


    May 2017
  51. KOPPENHAGEN P, Dickreuter E, Cordes N
    Head and neck cancer cell radiosensitization upon dual targeting of c-Abl and beta1-integrin.
    Radiother Oncol. 2017 May 31. pii: S0167-8140(17)30375.
    PubMed     Text format     Abstract available


  52. CHEN J, Cai W, Zheng X, Chen Y, et al
    The pattern of cervical lymph node metastasis in thoracic esophageal squamous cell carcinoma may affect the target decision for definitive radiotherapy.
    Radiother Oncol. 2017 May 24. pii: S0167-8140(17)30152.
    PubMed     Text format     Abstract available


  53. LAI TY, Wang TH, Liu CJ, Chao TF, et al
    Risk factors for osteonecrosis of the jaw in oral cancer patients after surgery and eventual adjuvant treatment: The potential role of chemotherapy.
    Radiother Oncol. 2017 May 19. pii: S0167-8140(17)30362.
    PubMed     Text format     Abstract available


  54. FAN CY, Lin CS, Chao HL, Huang WY, et al
    Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy: A Population-Based Cohort Study.
    Radiother Oncol. 2017 May 19. pii: S0167-8140(17)30367.
    PubMed     Text format     Abstract available


  55. CHRISTIAENS M, Collette S, Overgaard J, Gregoire V, et al
    Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure.
    Radiother Oncol. 2017 May 4. pii: S0167-8140(17)30160.
    PubMed     Text format     Abstract available


    April 2017
  56. LIN SH, Merrell KW, Shen J, Verma V, et al
    Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer.
    Radiother Oncol. 2017 Apr 25. pii: S0167-8140(17)30154.
    PubMed     Text format     Abstract available


  57. WELZ S, Monnich D, Pfannenberg C, Nikolaou K, et al
    Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial.
    Radiother Oncol. 2017 Apr 20. pii: S0167-8140(17)30144.
    PubMed     Text format     Abstract available


  58. RUSTHOVEN CG, Lanning RM, Jones BL, Amini A, et al
    Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy.
    Radiother Oncol. 2017 Apr 19. pii: S0167-8140(17)30130.
    PubMed     Text format     Abstract available


  59. ZHU H, Song H, Chen G, Yang X, et al
    eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma.
    Radiother Oncol. 2017 Apr 18. pii: S0167-8140(17)30140.
    PubMed     Text format     Abstract available


  60. YAMASHITA H, Abe O, Nakagawa K
    Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of 18FDG-PET scans: A long follow-up results of phase II study.
    Radiother Oncol. 2017 Apr 17. pii: S0167-8140(17)30141.
    PubMed     Text format    


  61. WU B, Kusters M, Kunze-Busch M, Dijkema T, et al
    Cross-institutional knowledge-based planning (KBP) implementation and its performance comparison to Auto-Planning Engine (APE).
    Radiother Oncol. 2017;123:57-62.
    PubMed     Text format     Abstract available


    March 2017
  62. NEVENS D, Duprez F, Daisne JF, Schatteman J, et al
    Recurrence patterns after a decreased dose of 40Gy to the elective treated neck in head and neck cancer.
    Radiother Oncol. 2017 Mar 22. pii: S0167-8140(17)30099.
    PubMed     Text format     Abstract available


  63. LIGTENBERG H, Jager EA, Caldas-Magalhaes J, Schakel T, et al
    Modality-specific target definition for laryngeal and hypopharyngeal cancer on FDG-PET, CT and MRI.
    Radiother Oncol. 2017 Mar 1. pii: S0167-8140(17)30064.
    PubMed     Text format     Abstract available


  64. NAKAMURA N, Zenda S, Tahara M, Okano S, et al
    Proton beam therapy for olfactory neuroblastoma.
    Radiother Oncol. 2017;122:368-372.
    PubMed     Text format     Abstract available


    February 2017
  65. ZSCHAECK S, Lock S, Leger S, Haase R, et al
    FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy.
    Radiother Oncol. 2017 Feb 17. pii: S0167-8140(17)30047.
    PubMed     Text format     Abstract available


  66. HAMMING-VRIEZE O, van Kranen SR, Heemsbergen WD, Lange CA, et al
    Analysis of GTV reduction during radiotherapy for oropharyngeal cancer: Implications for adaptive radiotherapy.
    Radiother Oncol. 2017;122:224-228.
    PubMed     Text format     Abstract available


  67. SODERSTROM K, Nilsson P, Laurell G, Zackrisson B, et al
    Dysphagia - Results from multivariable predictive modelling on aspiration from a subset of the ARTSCAN trial.
    Radiother Oncol. 2017;122:192-199.
    PubMed     Text format     Abstract available


    January 2017
  68. PATEL R, Barker HE, Kyula J, McLaughlin M, et al
    An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.
    Radiother Oncol. 2017 Jan 25. pii: S0167-8140(16)34478.
    PubMed     Text format     Abstract available


  69. FUCCIO L, Mandolesi D, Farioli A, Hassan C, et al
    Brachytherapy for the palliation of dysphagia owing to esophageal cancer: A systematic review and meta-analysis of prospective studies.
    Radiother Oncol. 2017 Jan 16. pii: S0167-8140(17)30003.
    PubMed     Text format     Abstract available


    November 2016
  70. THOR M, Owosho AA, Clark HD, Oh JH, et al
    Internal and external generalizability of temporal dose-response relationships for xerostomia following IMRT for head and neck cancer.
    Radiother Oncol. 2016 Nov 24. pii: S0167-8140(16)34380.
    PubMed     Text format     Abstract available


  71. LESZCZYNSKA KB, Dobrynin G, Leslie RE, Ient J, et al
    Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer.
    Radiother Oncol. 2016 Nov 10. pii: S0167-8140(16)34372.
    PubMed     Text format     Abstract available


  72. WANG L, Liu L, Han C, Liu S, et al
    The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy.
    Radiother Oncol. 2016 Nov 9. pii: S0167-8140(16)34370.
    PubMed     Text format     Abstract available


    October 2016
  73. QIU B, Wang D, Yang H, Xie W, et al
    Combined modalities of magnetic resonance imaging, endoscopy and computed tomography in the evaluation of tumor responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma.
    Radiother Oncol. 2016 Oct 25. pii: S0167-8140(16)34352.
    PubMed     Text format     Abstract available


  74. MARTINEZ-FERNANDEZ MI, Alcalde J, Cambeiro M, Peydro GV, et al
    Perioperative high dose rate brachytherapy (PHDRB) in previously irradiated head and neck cancer: Results of a phase I/II reirradiation study.
    Radiother Oncol. 2016 Oct 13. pii: S0167-8140(16)34287.
    PubMed     Text format     Abstract available


    August 2016
  75. HE L, Chapple A, Liao Z, Komaki R, et al
    Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer.
    Radiother Oncol. 2016 Aug 22. pii: S0167-8140(16)31243.
    PubMed     Text format     Abstract available


  76. NEVENS D, Duprez F, Daisne JF, Dok R, et al
    Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control.
    Radiother Oncol. 2016 Aug 12. pii: S0167-8140(16)34247.
    PubMed     Text format     Abstract available


  77. CHUTER R, Prestwich R, Bird D, Scarsbrook A, et al
    The use of deformable image registration to integrate diagnostic MRI into the radiotherapy planning pathway for head and neck cancer.
    Radiother Oncol. 2016 Aug 3. pii: S0167-8140(16)31212.
    PubMed     Text format     Abstract available


    July 2016
  78. LOIMU V, Seppala T, Kapanen M, Tuomikoski L, et al
    Diffusion-weighted magnetic resonance imaging for evaluation of salivary gland function in head and neck cancer patients treated with intensity-modulated radiotherapy.
    Radiother Oncol. 2016 Jul 27. pii: S0167-8140(16)31200.
    PubMed     Text format     Abstract available


  79. WONG KH, Kuciejewska A, Sharabiani MT, Ng-Cheng-Hin B, et al
    A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer.
    Radiother Oncol. 2016 Jul 5. pii: S0167-8140(16)31174.
    PubMed     Text format     Abstract available


    June 2016
  80. BROUWER CL, Steenbakkers RJ, van der Schaaf A, Sopacua CT, et al
    Selection of head and neck cancer patients for adaptive radiotherapy to decrease xerostomia.
    Radiother Oncol. 2016 Jun 23. pii: S0167-8140(16)31149.
    PubMed     Text format     Abstract available


  81. LIN P, Min M, Lee M, Holloway L, et al
    Prognostic utility of 18F-FDG PET-CT performed prior to and during primary radiotherapy for nasopharyngeal carcinoma: Index node is a useful prognostic imaging biomarker site.
    Radiother Oncol. 2016 Jun 16. pii: S0167-8140(16)31124.
    PubMed     Text format     Abstract available


  82. MATUSCHEK C, Bolke E, Geigis C, Kammers K, et al
    Influence of dosimetric and clinical criteria on the requirement of artificial nutrition during radiotherapy of head and neck cancer patients.
    Radiother Oncol. 2016 Jun 10. pii: S0167-8140(16)31120.
    PubMed     Text format     Abstract available


    May 2016
  83. CHEN CY, Li CC, Chien CR
    Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? A population based propensity-score matched analysis.
    Radiother Oncol. 2016 May 17. pii: S0167-8140(16)31089.
    PubMed     Text format     Abstract available


  84. KJAER T, Dalton SO, Andersen E, Karlsen R, et al
    A controlled study of use of patient-reported outcomes to improve assessment of late effects after treatment for head-and-neck cancer.
    Radiother Oncol. 2016 May 10. pii: S0167-8140(16)31080.
    PubMed     Text format     Abstract available


  85. JANSSENS GO, Langendijk JA, Terhaard CH, Doornaert PA, et al
    Quality-of-life after radiotherapy for advanced laryngeal cancer: Results of a phase III trial of the Dutch Head and Neck Society.
    Radiother Oncol. 2016 May 7. pii: S0167-8140(16)00111.
    PubMed     Text format     Abstract available


    April 2016
  86. PALMA B, Bazalova-Carter M, Hardemark B, Hynning E, et al
    Assessment of the quality of very high-energy electron radiotherapy planning.
    Radiother Oncol. 2016;119:154-8.
    PubMed     Text format     Abstract available


    March 2016
  87. HATTON MQ, Hill R, Fenwick JD, Morgan SA, et al
    Continuous hyperfractionated accelerated radiotherapy - Escalated dose (CHART-ED): A phase I study.
    Radiother Oncol. 2016;118:471-7.
    PubMed     Text format     Abstract available


  88. JANSSENS G, Smeets J, Vander Stappen F, Prieels D, et al
    Sensitivity study of prompt gamma imaging of scanned beam proton therapy in heterogeneous anatomies.
    Radiother Oncol. 2016;118:562-7.
    PubMed     Text format     Abstract available


    February 2016
  89. HONG A, Zhang X, Jones D, Veillard AS, et al
    Relationships between p53 mutation, HPV status and outcome in oropharyngeal squamous cell carcinoma.
    Radiother Oncol. 2016;118:342-9.
    PubMed     Text format     Abstract available



  90. Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy.
    Radiother Oncol. 2016;118:304-14.
    PubMed     Text format     Abstract available


  91. LYHNE NM, Johansen J, Kristensen CA, Andersen E, et al
    Pattern of failure in 5001 patients treated for glottic squamous cell carcinoma with curative intent - A population based study from the DAHANCA group.
    Radiother Oncol. 2016;118:257-66.
    PubMed     Text format     Abstract available


  92. LEE JY, Sun JM, Oh DR, Lim SH, et al
    Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02).
    Radiother Oncol. 2016;118:244-50.
    PubMed     Text format     Abstract available


  93. ZENDA S, Akimoto T, Mizumoto M, Hayashi R, et al
    Phase II study of proton beam therapy as a nonsurgical approach for mucosal melanoma of the nasal cavity or para-nasal sinuses.
    Radiother Oncol. 2016;118:267-71.
    PubMed     Text format     Abstract available


    October 2015
  94. NEVENS D, Deschuymer S, Langendijk JA, Daisne JF, et al
    Validation of the total dysphagia risk score (TDRS) in head and neck cancer patients in a conventional and a partially accelerated radiotherapy scheme.
    Radiother Oncol. 2015 Oct 15. pii: S0167-8140(15)00550.
    PubMed     Text format     Abstract available


  95. DE BREE R, van der Putten L, van Tinteren H, Wedman J, et al
    Effectiveness of an F-FDG-PET based strategy to optimize the diagnostic trajectory of suspected recurrent laryngeal carcinoma after radiotherapy: The RELAPS multicenter randomized trial.
    Radiother Oncol. 2015 Oct 15. pii: S0167-8140(15)00552.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Otorhinolaryngology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: